REVIEW article
Front. Immunol.
Sec. Microbial Immunology
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1523584
This article is part of the Research TopicGut Microbiota and Local Immune System in Colorectal and Liver CancerView all articles
Gut microbiota -bidirectional modulator: role in inflammatory bowel disease and colorectal cancer
Provisionally accepted
- 1Endoscopy Center, China Japan Union Hospital of Jilin University, Changchun, China
- 2The Third Affiliated Clinical Hospital of Changchun University of Traditional Chinese Medicine, Jilin, China
- 3Jilin University, Changchun, Hebei Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The gut microbiota is a diverse ecosystem that significantly impacts human health and disease.This article focuses on how the gut microbiota interacts with inflammatory bowel diseases and colorectal tumors, especially through immune regulation. The gut microbiota plays a role in immune system development and regulation, while the body's immune status can also affect the composition of the microbiota. These microorganisms exert pathogenic effects or correct disease states in gastrointestinal diseases through the actions of toxins and secretions, inhibition of immune responses, DNA damage, regulation of gene expression, and protein synthesis. The microbiota and its metabolites are essential in the development and progression of inflammatory bowel diseases and colorectal tumors.The complexity and bidirectionality of this connection with tumors and inflammation might render it a new therapeutic target. Hence, we explore therapeutic strategies for the gut microbiota, highlighting the potential of probiotics and fecal microbiota transplantation to restore or adjust the microbial community.Additionally, we address the challenges and future research directions in this area concerning inflammatory bowel diseases and colorectal tumors.
Keywords: Gut Microbiota, CRC, IBD, Immune Modulation, SCFAs
Received: 06 Nov 2024; Accepted: 08 Apr 2025.
Copyright: © 2025 Cui, Li, Zhong, Liu, Xiao, Liu, Zhao and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Changfeng Li, Endoscopy Center, China Japan Union Hospital of Jilin University, Changchun, China
Wei Yang, Jilin University, Changchun, 130012, Hebei Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.